Finn
RARE Biotechnology · Rare disease · Gene therapy · Commercial biotech · Thesis updated November 8, 2026

Approvals and voucher sales secure the 2027 profit plan

01 Running thesis

A cleared financial runway meets a depleted pipeline

Ultragenyx transformed its business in late 2026. The FDA approved two major gene therapies, GENGLYCOS for glycogen storage disease type Ia and FAYUVI for Sanfilippo syndrome. By selling the associated priority review vouchers for $350 million, management secured the balance sheet and cleared the path to their 2027 profitability target.

While the commercial side is winning, the clinical pipeline took a massive hit. The company terminated its GTX-102 program for Angelman syndrome after a Phase 3 failure and ended its UX701 program for Wilson disease due to poor efficacy. This forced a 20 percent workforce reduction to realign spending.

Finn's view acknowledges the sharply altered reality. The financial overhang is gone, and the company is no longer waiting on binary FDA decisions. However, with the late-stage pipeline hollowed out, the entire growth story now rests on executing the commercial launches of GENGLYCOS and FAYUVI without stumbling.

Nov 2026→The FDA approved GENGLYCOS and FAYUVI, and the resulting vouchers sold for $350 million. However, GTX-102 and UX701 failed in the clinic, triggering a 20 percent workforce cut.
Aug 2026▼The Q2 2026 10-Q disclosed an additional ANDA filing for a generic version of Dojolvi by Sun Pharma, which expands the ongoing patent litigation risk for one of the company's commercial assets.
Aug 2026▲Q2 2026 brought record revenue of $214 million and 50 percent growth for Evkeeza. Management also confirmed the 2027 profitability target relies on selling priority review vouchers for upcoming gene therapy approvals.
May 2026→Q1 revenue slipped to $136 million from $139 million, mainly because of Crysvita order timing in Latin America. The update also added a possible UX143 regulatory discussion after failed Phase 3 studies, and new Dojolvi ANDA litigation.
May 2026▲Management gave firm FDA action dates for DTX401 and UX111 in Q3 2026 and kept 2026 revenue guidance at $730 million to $760 million. That made the next 12 months easier to track.
Feb 2026▼The 2025 10-K confirmed that UX143 failed both Phase 3 studies and that UX111 received an Incomplete Response Letter tied to CMC documentation. The story became more dependent on the remaining gene therapy pipeline.
Feb 2026→Ultragenyx reported $673 million of 2025 revenue, up 20 percent year over year, but guided to slower 2026 growth of 8 to 13 percent. The company also announced a 10 percent workforce reduction to target profitability in 2027.
Nov 2025▲The Q3 2025 filing showed product demand still growing and confirmed key pipeline timing for DTX401 and UX701. It also made the 2027 profitability goal a clear watch item.
02 Business model

Small patient groups, high stakes

Ultragenyx finds, develops, and sells drugs for rare and ultra-rare diseases. These illnesses affect small patient groups, so each drug serves a limited number of people. The payoff comes from high prices and limited direct competition for these highly specialized treatments.

Money flows from product sales of Crysvita, Dojolvi, Evkeeza, Mepsevii, and now the newly approved GENGLYCOS and FAYUVI. Crysvita is the main revenue driver. Ultragenyx sells directly in some markets, like Latin America, and receives collaboration revenue from partners in North America and Europe.

The company expects to reach profitability in 2027. That timeline is now fully funded by the $350 million sale of priority review vouchers in October 2026. To protect this timeline after recent clinical failures, management cut 20 percent of the workforce to strictly control expenses.

The moat relies on specialized knowledge in finding rare disease patients and dealing with complex regulators. The weakness is the binary nature of clinical trials, where years of investment can vanish overnight when a drug fails a late-stage test.

03 Product portfolio

What sells now, what could matter next

Cash cow

Crysvita

Crysvita treats X-linked hypophosphatemia and tumor-induced osteomalacia. It is the main revenue driver, contributing $156 million in Q2 2026.

Growth engine

GENGLYCOS

An FDA-approved gene therapy for glycogen storage disease type Ia. Commercial launch metrics in early 2027 are the next major focus.

Growth engine

FAYUVI

An FDA-approved gene therapy for Sanfilippo syndrome. Like GENGLYCOS, its initial launch trajectory will dictate near-term growth.

Growth engine

Evkeeza

Evkeeza treats homozygous familial hypercholesterolemia. It was the strongest commercial grower in Q2 2026, with sales up 50 percent year over year to $21 million.

Steady

Dojolvi

Dojolvi treats long-chain fatty acid oxidation disorders. It brought in $27 million in Q2 2026, though generic litigation remains a legal threat.

Steady

Mepsevii

Mepsevii treats MPS VII, a very rare genetic disease. It contributed $10 million in Q2 2026.

Option

DTX301

A gene therapy for ornithine transcarbamylase deficiency. Phase 3 study enrollment is complete with data expected in the first half of 2027.

Option

UX143

UX143 is being studied for osteogenesis imperfecta. Its Phase 3 trials failed, and the regulatory path forward remains uncertain and potentially expensive.

04 Business segments

Q2 product mix leans heavily on Crysvita

Crysvita73%modest
Dojolvi13%modest
Evkeeza10%growing fast
Mepsevii and other revenue4%flat

The mix below uses Q2 2026 total revenue of $214 million. Crysvita accounted for $156 million, Dojolvi for $27 million, Evkeeza for $21 million, and Mepsevii for $10 million.

05 Risk factors

What could go wrong

Gene therapy launch execution

High impact · Medium odds

With the late-stage pipeline gutted by recent clinical failures, all growth expectations sit on the commercial rollout of GENGLYCOS and FAYUVI. Any delay in activating treatment centers or enrolling patients will directly threaten the 2027 profitability plan.

We watchInitial QTC activation and start forms reported in early 2027.

Expanding Dojolvi generic challenges

Medium impact · Medium odds

Somerset and Sun Pharma filed ANDAs seeking approval for generic versions of Dojolvi. Ultragenyx filed patent infringement suits in response. An unfavorable legal outcome could pressure a product that contributes meaningful steady sales.

We watchCourt rulings, settlement terms, or FDA actions linked to Dojolvi ANDA filers.

UX143 regulatory dead end

Medium impact · High odds

UX143 failed its Phase 3 endpoints in late 2025. The UK MHRA indicated a new randomized study is likely needed. If the FDA also demands a new trial instead of alternative fracture analyses, the program may become too expensive to salvage.

We watchFDA meeting feedback regarding alternative fracture analyses.
06 Quick answers

In one breath

What does Ultragenyx do?

Ultragenyx develops and sells treatments for rare and ultra-rare diseases. Its commercial drugs include Crysvita, Dojolvi, Evkeeza, Mepsevii, and newly approved gene therapies GENGLYCOS and FAYUVI.

Did Ultragenyx get FDA approval for its gene therapies?

Yes. The FDA approved GENGLYCOS for glycogen storage disease type Ia and FAYUVI for Sanfilippo syndrome in August and September of 2026.

Is Ultragenyx profitable?

The company expects to reach profitability in 2027. This plan was recently secured when they sold two priority review vouchers for $350 million to fund their operations.

What happened to the Angelman syndrome drug?

The GTX-102 program for Angelman syndrome failed its Phase 3 clinical trial in late 2026. Ultragenyx terminated the program and cut 20 percent of its workforce to reduce costs.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Ultragenyx Q3 2026 earnings transcript
  2. Ultragenyx Q2 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Ultragenyx Pharmaceutical Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today